Anthrax: From antiquity to answers

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 471-473

  Artenstein, Andrew W ^a  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; CYCLIC AMP; CYTOKINE; NITRIC OXIDE;

ANTHRAX; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; BLOOD VESSEL PERMEABILITY; CYTOKINE RELEASE; DENDRITIC CELL; EDITORIAL; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INHALATION; INTOXICATION; LETHALITY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MORBIDITY; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HUMANS; RATS; VIRULENCE FACTORS;

EID: 33846787177     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510859     Document Type: Editorial

References (38)

1. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-52.
2. Centers for Disease Control and Prevention. Biological and chemical terrorism: strategic plan for preparedness and response. MMWR Morb Mortal Wkly Rep 2000; 49 (RR-4):1-14.
3. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci USA 2003; 100:4346-51.
4. Holty J-EC, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-80.
5. Duesbery NS, Vande Woude GF. Anthrax toxins. Cell Mol Life Sci 1999; 55:1599-609.
6. Banks DJ, Ward SC, Bradley KA. New insights into the functions of anthrax toxin. Expert Rev Mol Med 2006; 8:1-18.
7. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 1986; 261:7123-6.
8. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Nad Acad Sci USA 1993; 90:10198-201.
9. Moayeri M, Martinez NW, Wiggins J, Young HA, Leppla SH. Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity. Infect Immun 2004; 72:4439-47.
10. Moayeri M, Haines D, Young HA, Leppla SH. Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J Clin Invest 2003; 112:670-82.
11. Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 1986; 51:795-800.
12. Baldari CT, Tonello F, Paccani SR, Montecucco C. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol 2006; 27:434-40.
13. Cordoba-Rodriguez R, Fang H, Lankford CSR, Frucht DM. Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1β and IL-18. J Biol Chem 2004; 279:20563-6.
14. Dang O, Navarro L, Anderson K, David M. Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J Immunol 2004; 172:747-51.
15. During RL, Li W, Hao B, et al. Anthrax lethal toxin paralyzes neutrophil actin-based mobility. J Infect Dis 2005; 192:837-45.
16. Agrawal A, Lingappa J, Leppla SH, et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003; 424:329-34.
17. Comer JE, Chopra AK, Peterson JW, König R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 2005; 73:8275-81.
18. Fang H, Xu L, Chen TY, Cyr JM, Frucht DM. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J Immunol 2006; 176:6155-61.
19. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993; 90:2291-4.
20. Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003; 163:701-9.
21. Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 2004; 72:430-9.
22. Steele AD, Warfel JM, D'Agnillo FD. Anthrax lethal toxin enhances cytokine-induced VCAM-1 expression on human endothelial cells. Biochem Biophys Res Commun 2005; 337:1249-56.
23. Gozes Y, Moayeri M, Wiggins JF, Leppla SH. Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006; 74:1266-72.
24. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc Natl Acad Sci USA 1982; 79:3162-6.
25. Hoover DL, Friedlander AM, Rogers LC, Yoon I-K, Warren RL, Cross AS. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun 1994; 62:4432-9.
26. Pezard C, Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun 1991; 59:3472-7.
27. Tournier J-N, Quesnel-Hellmann A, Mathieu J, et al. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol 2005; 174:4934-41.
28. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. Effects of anthrax toxin components on human neutrophils. Infect Immun 1985; 47:306-10.
29. Crawford MA, Aylott CV, Bourdeau RW, Bokoch GM. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J Immunol 2006; 176:7557-65.
30. Firoved AM, Miller GF, Moayeri M, et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 2005; 167:1309-20.
31. Cui X, Li Y, Li X, et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007; 195:572-80 (in this issue).
32. Fish DC, Klein F, Lincoln RE, Walker JS, Dobbs JP. Pathophysiological changes in the rat associated with anthrax toxin. J Infect Dis 1968; 118:114-24.
33. Opal SM, Artenstein AW, Cristofaro PA, et al. Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication. Infect Immun 2005; 73:5101-5.
34. Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem 2006; 49:5232-44.
35. Karginov VA, Nestorovich EM, Moayeri M, Leppla SH, Bezrukov SM. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci USA 2005; 102:15075-80.
36. Scobie HM, Thomas D, Marlett JM, et al. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis 2005; 192:1047-51.
37. Artenstein AW, Opal SM, Cristofaro PA, et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J Infect Dis 2004; 190:1655-60.
38. Shen Y, Zhukovskaya NL, Zimmer MI, et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101:3242-7.